ReleaseWire Connect

In order to thwart microbial growth and render the product contamination free, packaging plays a vital role and serves the purpose of safety throughout the shelf life of pharmaceuticals. In regulatory perspective, packaging has gained a significant importance and need critical compliance. The packaging equipment market for pharmaceutical has evolved from conventional packaging systems to modern and automated system, and it is well on its way to further growth. Our study suggests that packaging equipment market for pharmaceutical is expected to grow at a healthy CAGR from 2013 to 2020. This report analyses the global packaging equipment market for pharmaceutical, and investigates the reasons for its growth. The study investigates different market segments and identifies the most beneficial among them. The analysis creates the absolute picture of competition and recognizes the strategies of key leaders.

Illegal drug is non-prescribed type of drug taken for non-medicinal reasons that affects physical and mental health of addicts. According to National Survey on Drug Use and Health, 19.9 million Americans use illegal drugs in a month. There were more than 208 million people consuming illegal drugs worldwide. Change in life style attracts younger people to consume illicit drugs, which is a major driver for the drug abuse testing market. There are 253,000 death occurred due to consumption of illicit drugs out of which 1.3% are of the age between 15-35 years in US. Increase in variety of drug consumption ceases the flexibility of drug testing devices. Increase in drug variety creates complexities in identifying drug level in drug testing devices, this stands as a major restraints for the market.

Ovarian cancer is cancer that affects the ovaries. According to the WHO, an estimated 2,38,700 women were diagnosed with ovarian cancer in 2012. The report analyzes the demand for ovarian cancer drugs, which would contribute to the growth of the ovarian cancer drugs market. It focuses on both generic and brand drugs that are used to treat ovarian cancer and their impact on the market.

Clinical nutrition products are type of pharmaceutical products, which help to keep patient healthy. They aid to improve metabolic system of the body by providing adequate supplements such as minerals, vitamins and others. Rising instances of chronic and lifestyle diseases and increasing population that receives malnutrition treatment are the major factors responsible for driving the growth of the clinical nutrition market. Furthermore, rise in global population, disposable income, premature births, investment from major players & governments, and awareness among people are expected to drive the growth of the market. However, stringent regulatory scenario and tolerability issues are expected to slow down the growth of the market.

Breast cancer is one of the most common type of malignant cancers, which is prevalent in women above 40 years. As per World Health Organization (WHO) estimates, breast cancer accounted for around 521,000 deaths globally in 2012. Generally, hormone therapies are used for treating breast cancer, which subsequently leads to resistance after continuous use of hormone therapy. This resistance towards hormone therapy is termed as hormone refractory breast cancer. Hence, there is an increasing need for the effective treatment in hormone refractory breast cancer market. The market holds immense future potential, as there is no standard therapy, approved for hormone refractory breast cancer. However, there are rising hopes to get approved therapies in near future as drugs such as trastuzumab and everolimus, alone or in combination, are under development for the effective treatment of hormone refractory breast cancers.

Breast cancer is the most common type of malignant cancer prevalent in women above the age of 40. According to the estimates of World Health Organization, cancer is the most fatal human disease accounting for the deaths of ~8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed ~521,000 individuals. Presently, increasing number of hormone therapies have made refractory breast cancers resistant toward therapeutics, termed as hormone-resistant breast cancers. However, recently developed hormone refractory breast cancer chemotherapeutic agents such as, trastuzumab and everolimus, alone or in combination, are under clinical trials for the effective treatment of hormone refractory breast cancers.

Antibody drug conjugates (ADCs), also known as anti-cancer drugs are promising and effective modalities for cancer therapies. The ADCs are prepared by combining two principles i.e. monoclonal antibody specificity and cell killing efficacy of HPAPI (highly potent active pharmaceutical ingredient). This combinational approach specifically kills the cancer cells by a toxic payload through binding and internalizing ADC into the cancerous cells. Several years of extensive biological research and developments in the pharmaceutical sector have led to the development of the worlds first two ADCs namely Adcetris and Kadcyla for cancer therapy. The Antibody drug conjugates (ADCs) market is yet dormant as only two drugs are approved and commercialized till date. Adcetris from Seattle Genetics received the FDA approval in 2011 for the treatment of systemic anaplastic large cell lymphoma and Hodgkins lymphoma. Kadcyla, a product from Genentech, used in the treatment of breast cancer received the FDA approval in 2013.

The RNA-based therapeutics involves broad range of the RNA-based technologies, which help the patients to diagnose or treat various chronic diseases. The RNA-based therapeutics play a crucial role in providing the accurate and precise healthcare treatments, which helps in treating the disease at molecular and sub-molecular levels. RNA-based therapeutic modalities provide beneficial business opportunities due to its rising acceptance, technological advancements and targeted drug delivery of these therapeutics as compared to the other treatment modalities (synthetic therapeutics). The Asia-Pacific RNA-based therapeutics market is growing at a promising CAGR due to the gene silencing potential of these therapeutics. However, the market is still at the nascent stage in developing regions such as India and witnessing the lucrative growth rate during the analysis period. Factors that would fuel the market growth in Asia-Pacific region are target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, high cost coupled with the high failure rates and reimbursement issues related with the adoption of RNA-based therapeutics would restrain the market growth.

Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and medical research organizations (CROs) are largely benefitted by the exceptional properties of nonmaterial and exploit it for various applications including diagnosis and treatment of diseases. The Asia pacific nanomedicine market is majorly driven by advancement in nanomedicine technologies, government initiatives, growing investment in research funding, better understanding of technical know-how and a high prevalence of chronic diseases. However, the cost of materials used in nanotechnology study along with the insufficient regulatory framework can pose a major restrain for the growth of the Asia pacific nanomedicines market. Presence of high growth opportunities in nanomedicines would provide significant benefits to emerging economies such as India and China due to the impending healthcare needs in this location.

Proteins play a crucial role in maintaining both structural and functional aspects of an individual organism. Long chain of amino acids makes up a protein molecule and regulates all biological functions such as metabolic reactions, DNA replication and other vital expressional functions in the body. Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic agents and include a broad range of products such as growth factors, hormones, vaccines, monoclonal antibodies, cytokines and few others. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bioreactivity and success rate in treating life-threatening diseases and injuries. Rising prevalence of diseases such as cancer, diabetes, heart diseases, asthma and others is the crucial driver of the bioengineered protein drugs market.